Leerink Partnrs Has Strong Estimate for Hologic Q1 Earnings

Hologic, Inc. (NASDAQ:HOLX - Free Report) - Equities researchers at Leerink Partnrs boosted their Q1 2026 EPS estimates for shares of Hologic in a report released on Monday, July 21st. Leerink Partnrs analyst P. Souda now forecasts that the medical equipment provider will post earnings per share of $1.11 for the quarter, up from their previous estimate of $1.10. The consensus estimate for Hologic's current full-year earnings is $4.28 per share. Leerink Partnrs also issued estimates for Hologic's Q2 2026 earnings at $1.11 EPS and FY2027 earnings at $4.88 EPS.

A number of other analysts have also weighed in on the company. Morgan Stanley cut their price objective on Hologic from $77.00 to $65.00 and set an "equal weight" rating on the stock in a research report on Monday, May 5th. Citigroup raised Hologic from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $60.00 to $80.00 in a research report on Wednesday, July 9th. Evercore ISI upped their price objective on Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a research report on Tuesday, July 8th. Royal Bank Of Canada cut their price objective on Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a research report on Friday, May 2nd. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Hologic in a research note on Tuesday, May 27th. Eleven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Hologic presently has a consensus rating of "Hold" and an average target price of $77.33.

Hologic Stock Up 0.6%

Shares of Hologic stock traded up $0.40 during trading hours on Wednesday, reaching $66.50. 1,116,538 shares of the company were exchanged, compared to its average volume of 1,795,352. Hologic has a 1 year low of $51.90 and a 1 year high of $84.67. The stock's fifty day moving average is $63.33 and its 200 day moving average is $63.00. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.52 and a current ratio of 3.24. The firm has a market cap of $14.82 billion, a PE ratio of 28.06, a PEG ratio of 2.42 and a beta of 0.55.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 13.83% and a return on equity of 19.71%. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. During the same quarter last year, the firm earned $1.03 EPS. The firm's revenue for the quarter was down 1.2% on a year-over-year basis.

Hedge Funds Weigh In On Hologic

Several large investors have recently bought and sold shares of HOLX. Victory Capital Management Inc. raised its holdings in shares of Hologic by 34.4% in the first quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider's stock valued at $408,283,000 after buying an additional 1,692,177 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Hologic by 2.6% in the fourth quarter. Geode Capital Management LLC now owns 5,732,131 shares of the medical equipment provider's stock valued at $412,159,000 after buying an additional 144,838 shares during the last quarter. Invesco Ltd. raised its holdings in shares of Hologic by 18.8% in the first quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider's stock valued at $298,655,000 after buying an additional 764,573 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in shares of Hologic by 1.6% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,473,098 shares of the medical equipment provider's stock valued at $276,303,000 after buying an additional 69,878 shares during the last quarter. Finally, Ameriprise Financial Inc. raised its holdings in shares of Hologic by 0.8% in the first quarter. Ameriprise Financial Inc. now owns 3,512,594 shares of the medical equipment provider's stock valued at $216,973,000 after buying an additional 29,133 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.

Insider Transactions at Hologic

In related news, Director Martin D. Madaus acquired 5,445 shares of the firm's stock in a transaction on Wednesday, May 7th. The stock was bought at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the completion of the purchase, the director directly owned 5,445 shares of the company's stock, valued at approximately $300,781.80. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 1.88% of the stock is owned by corporate insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.